The role of Self-Nanoemulsifying drug delivery systems of CDODA-Me in sensitizing Erlotinib-Resistant non–small cell lung cancer

E Nottingham, V Sekar, A Mondal, S Safe… - Journal of …, 2020 - Elsevier
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …
被引用次数：20 相关文章
[PDF] nsf.gov

[PDF][PDF] The role of Self Nano Emulsifying drug delivery systems of CDODA-Me in sensitizing Erlotinib resistant Nonsmall cell lung cancer

E Nottingham - Journal of pharmaceutical sciences, 2020 - par.nsf.gov
abstract We have investigated the effects of combination treatment involving ERL (erlotinib)
with a glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing …

The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer

E Nottingham, V Sekar, A Mondal… - Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …

The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non–Small Cell Lung Cancer

E Nottingham, V Sekar, A Mondal, S Safe… - Journal of …, 2020 - jpharmsci.org
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …

The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer.

E Nottingham, V Sekar, A Mondal, S Safe… - Journal of …, 2020 - europepmc.org
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …
[HTML] nih.gov

[HTML][HTML] The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non–Small Cell Lung Cancer

E Nottingham, V Sekar, A Mondal, S Safe… - Journal of …, 2020 - ncbi.nlm.nih.gov
We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …